Boehringer Ingelheim Corporation Release: Sub-Analysis Shows Primary Benefits seen with RE-LY(R) are Independent of Level of Centre-Based International Normalized Ratio Control

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that results from a pre-specified sub-group analysis of the RE-LY® study (Randomized Evaluation of Long-Term Anticoagulation Therapy, Warfarin, Compared with Dabigatran) – the largest atrial fibrillation outcomes trial ever completed - were published in The Lancet. 1 The sub-group analysis assessed the effects of centre-based international normalized ratio (INR) control on study outcomes.